Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

West Virginia Suit Vs. Medco Will Test Claim That PBM Favors Merck Drugs

Executive Summary

Medco will be defending itself in court against the oft-repeated allegation that it favors Merck products

You may also be interested in...



Medco Will Disclose Drug Cost After Rebates, Discounts Under Settlement

Medco will disclose drug costs after rebates and discounts when the PBM wants to make a therapeutic interchange to a product with a higher AWP

Medco Will Disclose Drug Cost After Rebates, Discounts Under Settlement

Medco will disclose drug costs after rebates and discounts when the PBM wants to make a therapeutic interchange to a product with a higher AWP

IG Rx Compliance Guide Sets PhRMA Marketing Code As Minimum Threshold

The HHS Inspector General's draft pharmaceutical industry compliance guide embraces the PhRMA marketing guidelines as a minimum standard for industry to follow

Latest Headlines
See All
UsernamePublicRestriction

Register

PS040822

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel